SCHEMBL10075558

SCHEMBL10075558

COC(=O)c1ccc(O)c2nc3c(CNCc4ccccc4)c(O)c(-c4c(O)c(CNCc5ccccc5)c5nc6c(O)ccc(C(=O)OC)c6nc5c4O)c(O)c3nc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
KDM4E B2RXH2 3/20 0.39
ALDH1A1 P00352 2/20 0.37
GAA P10253 1/20 0.37
HPGD P15428 1/20 0.37
CRHBP P24387 1/20 0.37
CRHR2 Q13324 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2D6 P10635 1/20 0.37
ALOX15 P16050 1/20 0.37
HIF1A Q16665 1/20 0.37
EGFR P00533 2/20 0.36
MAPT P10636 1/20 0.36
NOX4 Q9NPH5 1/20 0.36
PKM P14618 1/20 0.36
EGLN1 Q9GZT9 1/20 0.35
LMNA P02545 1/20 0.35
TSHR P16473 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10074598 0.86 HIF1A (0.44) MEN1KMT2AKDM4EALDH1A1CYP1A2
SCHEMBL10074409 0.84 KDM4E (0.40) MEN1KMT2AKDM4EGAAHPGD
SCHEMBL10075151 0.82 KDM4E (0.42) MEN1KMT2AKDM4EGAAHPGD
SCHEMBL10075152 0.81 KDM4E (0.38) MEN1KMT2AKDM4EGAAHPGD
SCHEMBL10075134 0.81 KDM4E (0.41) MEN1KMT2AKDM4EALDH1A1GAA
SCHEMBL10075153 0.79 KDM4E (0.40) MEN1KMT2AKDM4EALDH1A1GAA
SCHEMBL10074597 0.76 GSK3B (0.50) KMT2AGAAHPGDEGFREGLN1
SCHEMBL3724952 0.74 KDM4E (0.57) MEN1KMT2AKDM4EALDH1A1GAA
SCHEMBL16968749 0.72 KMT2A (0.35) MEN1KMT2AALDH1A1GAAHPGD
SCHEMBL3724957 0.72 KDM4E (0.51) MEN1KMT2AKDM4EGAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9351971-B2 Substituted 2,2′-biphenazines for treating diseases EUTROPICS PHARMACEUTICALS, INC. (US) 2016-05-31 US claimed
US-20150216862-A1 2,2'-BIPHENAZINE COMPOUNDS AND METHODS USEFUL FOR TREATING DISEASES EUTROPICS THERAPEUTICS, INC. 2015-08-06 US claimed
US-9351971-B2 Substituted 2,2′-biphenazines for treating diseases EUTROPICS PHARMACEUTICALS, INC. (US) 2016-05-31 US disclosed
US-9351971-B2 Substituted 2,2′-biphenazines for treating diseases EUTROPICS PHARMACEUTICALS, INC. (US) 2016-05-31 US disclosed
US-9351971-B2 Substituted 2,2′-biphenazines for treating diseases EUTROPICS PHARMACEUTICALS, INC. (US) 2016-05-31 US disclosed
US-20150216862-A1 2,2'-BIPHENAZINE COMPOUNDS AND METHODS USEFUL FOR TREATING DISEASES EUTROPICS THERAPEUTICS, INC. 2015-08-06 US disclosed
US-20150216862-A1 2,2'-BIPHENAZINE COMPOUNDS AND METHODS USEFUL FOR TREATING DISEASES EUTROPICS THERAPEUTICS, INC. 2015-08-06 US disclosed
US-20150216862-A1 2,2'-BIPHENAZINE COMPOUNDS AND METHODS USEFUL FOR TREATING DISEASES EUTROPICS THERAPEUTICS, INC. 2015-08-06 US disclosed
US-8987271-B2 2,2′-biphenazine compounds and methods useful for treating disease EUTROPICS PHARMACEUTICALS, INC. (US) 2015-03-24 US disclosed
US-8987271-B2 2,2′-biphenazine compounds and methods useful for treating disease EUTROPICS PHARMACEUTICALS, INC. (US) 2015-03-24 US disclosed
US-8987271-B2 2,2′-biphenazine compounds and methods useful for treating disease EUTROPICS PHARMACEUTICALS, INC. (US) 2015-03-24 US disclosed
US-20120225851-A1 COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES EUTROPICS PHARMACEUTICALS, INC. (US) 2012-09-06 US disclosed
US-20120225851-A1 COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES EUTROPICS PHARMACEUTICALS, INC. (US) 2012-09-06 US disclosed
US-20120225851-A1 COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES EUTROPICS PHARMACEUTICALS, INC. (US) 2012-09-06 US disclosed
WO-2012088438-A1 COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES EUTROPICS PHARMACEUTICALS, INC. (US) 2012-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225851-A1 COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES MCL1, BCL3, BCL9 MEN1 521/4885KMT2A 2058/4885KDM4E 1427/4885
US-20150216862-A1 2,2'-BIPHENAZINE COMPOUNDS AND METHODS USEFUL FOR TREATING DISEASES MCL1, BCL3, BCL2L1 MEN1 455/4885KMT2A 429/4885KDM4E 709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.